We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Hemex Health

Hemex Health breaks traditional barriers with its innovative diagnostic system that expands the potential of diagnost... read more Featured Products: More products

Download Mobile App




First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

By LabMedica International staff writers
Posted on 08 Feb 2024
Print article
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's population, with 40,000 newborns diagnosed annually. Beta thalassemia patients often require lifelong transfusions for survival. Many individuals with the beta-thal trait are unaware of their condition and the risk of having a child with the disease if their partner also carries the trait. Consequently, early screening and timely diagnosis are critical for managing beta-thalassemia, both for genetic counseling to aid in family planning and for preventing and managing later clinical complications. Now, a beta thalassemia test offers an accurate and convenient solution, aiding couples in making informed reproductive decisions, ensuring proper maternal care, and facilitating early diagnosis in infants.

Hemex Health’s (Portland, OR, USA) Gazelle Hb Variant test is capable of identifying 19 hemoglobinopathy conditions, including both beta-thal disease and trait, and sickle cell disease and trait. The test runs on the Gazelle compact, rugged, battery-powered in vitro diagnostic device that is designed for cost-effective use by entry-level healthcare workers, even in areas with limited access, resources, or electricity. The device digitally captures patient information and results for storage, printing, or subsequent transmission. Approved for identifying sickle cell disease and beta-thalassemia in an increasing number of countries, Gazelle integrates miniaturized versions of trusted technologies, innovative optics, and artificial intelligence. Priced similarly to an iPhone, Gazelle offers low-cost individual tests. Its sensitive detection and precise quantification capabilities enable it to identify beta-thal disease or trait in infants as young as six months and sickle cell disease and trait in newborns as early as 37 weeks gestation.

A clinical study validating the Gazelle Hb Variant Test's diagnostic accuracy for beta thalassemia revealed that it correctly identified subjects with beta-thal major, beta-thal intermedia, and beta-thal trait with over 99% accuracy, compared to the laboratory gold standard of high-performance liquid chromatography (HPLC). The study concluded that Gazelle represents an affordable, rapid solution for beta-thal identification at the point of care. Its demonstrated ability to provide accurate, rapid results (available in 8 minutes) suggests Gazelle's suitability for widespread beta-thal testing at the point of care. The test's affordability and convenience could greatly facilitate informed reproductive decisions for millions of couples, ensure appropriate maternal care, and enable prompt diagnosis in infants.

“By combining accuracy and affordability with on-site accessibility, Gazelle can make a significant impact in areas of the world with a high prevalence of beta-thalassemia,” said Patti White, CEO of Hemex Health. “Before Gazelle, lab-based, high-volume batch testing, with its slow turn-around time, was the best option. With Gazelle, young adults can be conveniently tested at primary care centers or even at screening events at schools or other community centers.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: Prostate cancer cell image taken using a scanning electron microscope (Photo courtesy of LRI EM Unit)

New Discoveries of Prostate Cancer Evolution Pave Way for Genetic Test

Prostate cancer ranks as one of the most common cancers affecting men, and while it accounts for a significant number of male cancer fatalities, many men live with it rather than die from it.... Read more

Pathology

view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more

Industry

view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.